Global Blood Therapeutics Goes Head to Head With Novartis On Sickle Cell

Global Blood Therapeutics Goes Head to Head With Novartis On Sickle Cell

Source: 
Motley Fool
snippet: 

On Nov. 15, the U.S. Food and Drug Administration (FDA) approved Adakveo (crizanlizumab) to treat painful episodes called vaso-occlusive crises in patients with sickle cell disease. Will this approval give Adakveo's manufacturer Novartis (NYSE: NVS) a big enough head start against Global Blood Therapeutics (NASDAQ: GBT), which is awaiting FDA approval for its sickle cell disease drug voxelotor?